Bristol Myers buys Orbital Therapeutics for $1.5 billion-February 2024-www.financetom.com

Bristol Myers buys Orbital Therapeutics for $1.5 billion

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Bristol Myers buys Orbital Therapeutics for $1.5 billion

Oct 10, 2025 4:43 AM

Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb

said on Friday it will acquire privately held cell

therapy developer Orbital Therapeutics for $1.5 billion in cash.

Previous page： Berkshire Hathaway vice-chairman Charlie Munger dies aged 99 Next page： Second-hand shopping a $1-billion-plus business for Amazon in Europe

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Berkshire Hathaway vice-chairman Charlie Munger dies aged 99

Nov 28, 2023

Born in 1924, Munger would have turned 100 on New Year's day.

Second-hand shopping a $1-billion-plus business for Amazon in Europe

Nov 28, 2023

John Boumphrey, Amazon's UK Country Manager, told reporters that in the UK alone the online retail giant last year sold more than 4 million used or refurbished products at a discount.

Newsletter | M-cap of BSE-listed companies crosses $4 Trillion mark; Charlie Munger dies at 99 & more

Nov 29, 2023

From the m-cap of BSE-listed companies crossing the $4 Tn mark to the most memorable quotes by Charlie Munger, here's a rundown of 11 significant news stories to keep you in the know:

CNBC-TV18 Newsbreak Confirmed: Aster DM Health arm to sell Aster DM Healthcare FZC stake to Alpha GCC for $1.01 billion

Nov 28, 2023

Shares of Aster DM Healthcare Ltd ended at ₹332.65, down by ₹4.75, or 1.41%, on the BSE. Founded in 1987 from a single clinic in Dubai, Aster DM has a strong presence across primary, secondary, tertiary, and quaternary healthcare and runs 33 hospitals, 127 clinics, 527 pharmacies, and 229 labs and patient experience centres in six Gulf countries and India.